Open Access
Volume 23, Numéro 1, January-February 2016
Numéro d'article D112
Nombre de pages 8
Section Dossier: Lipids and Brain / Lipides et cerveau
Publié en ligne 27 novembre 2015
  • Akhondzadeh S, Tabatabaee M, Amini H, et al. 2007. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr. Res. 90: 179–185. [CrossRef] [PubMed] [Google Scholar]
  • Arvindakshan M, Sitasawad S, Debsikdar V, et al. 2003. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol. Psychiatry 53: 56–64. [CrossRef] [PubMed] [Google Scholar]
  • Bazan NG. 2006. Eicosanoids, docosanoids, platelet-activating factor and inflammation. In: Siegel GJ, Albers WR, Brady ST, Price DL, eds., Basic neurochemistry: Molecular, cellular, and medical aspects. 7th ed., Burlington, MA: Academic Press, pp. 575–591. [Google Scholar]
  • Bentsen H, Solberg DK, Refsum H, et al. 2011. Bimodal distribution of polyunsaturated fatty acids in schizophrenia suggests two endophenotypes of the disorder. Biol. Psychiatry 70: 97–105 [CrossRef] [PubMed] [Google Scholar]
  • Benyó Z, Gille Z, Kero J, Csiky M, et al. 2005. GPR109A (PUMA-G/HM74A) mediates nicotinic acid – induced flushing. J. Clin. Invest. 115: 3634–3640. [CrossRef] [PubMed] [Google Scholar]
  • Benyó Z, Gille A, Bennett CL, Clausen BE, Offermanns S. 2006. Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells. Mol. Pharmacol. 70: 1844–1849. [CrossRef] [PubMed] [Google Scholar]
  • Berger G, Yuen H, McGorry P. 2002. The topical niacin flush test in early psychosis (Abstract). Schizophr. Res. 53: S38. [Google Scholar]
  • Berman KF, Torrey EF, Daniel DG, Weinberger DR. 1992. Regional cerebral blood flow in monozygotic twins discordant and concordant for schizophrenia. Arch. Gen. Psychiatry. 49: 927–934. [CrossRef] [PubMed] [Google Scholar]
  • Bleuler E. 1920. Lehrbuch der Psychiatrie, Berlin: Springer reprinted English translation (1976) Textbook of psychiatry. New York: Arno Press. [Google Scholar]
  • Bosveld-van Haandel L, Knegtering R, Kluiter H, van den Bosch RJ 2006. Niacin skin flushing in schizophrenic and depressed patients and healthy controls. Psychiatry Res. 143: 303–306. [CrossRef] [PubMed] [Google Scholar]
  • Braff DL, Freedman R, Schork NJ, Gottesman II. 2007. Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr. Bull. 33: 21–32. [CrossRef] [PubMed] [Google Scholar]
  • Chang, S.S., Liu, C.M., Lin, S.H., et al. 2009. Impaired flush response to niacin skin patch among schizophrenia patients and their nonpsychotic relatives: the effect of genetic loading. Schizophr Bull 35: 213–221. [CrossRef] [PubMed] [Google Scholar]
  • Condray R, Yao JK. 2011 Cognition, dopamine and bioactive lipids in schizophrenia. Front. Biosci. S3: 298–330. [Google Scholar]
  • Conklin SM, Muldoon MF, Reddy RD, Yao JK. 2007. Fatty acids and psychiatric disorders. In: Chow C.K. ed., Fatty acids in foods and their health implications, 3rd ed. New York: Marcel Dekker, Inc., pp. 1229–1256. [Google Scholar]
  • Das I, Khan NS. 1998. Increased arachidonic acid induced platelet chemiluminescence indicates cyclooxygenase overactivity in schizophrenic subjects. Prostagland. Leukot. Essent. Fatty Acids 58: 165–168. [CrossRef] [Google Scholar]
  • Davis GC, Buchsbaum MS, van Kammen DP, Bunney WE Jr, 1979. Analgesia to pain stimuli in schizophrenics and its reversal by naltrexone. Psychiatry Res. 1: 61–69. [CrossRef] [PubMed] [Google Scholar]
  • Doris AB, Wahle K, MacDonald A, et al. 1998. Red cell membrane fatty acids, cytosolic phospholipase A2 and schizophrenia. Schizophr. Res. 31: 185–196. [CrossRef] [PubMed] [Google Scholar]
  • Eaton WW, Hayward C, Ram R. 1992. Schizophrenia and rheumatoid arthritis: a review. Schizophr. Res. 6: 181–192. [CrossRef] [PubMed] [Google Scholar]
  • Eklund B, Kaijser L, Nowak J, Wennmalm A. 1979. Prostaglandins contribute to the vasodilation induced by nicotinic acid. Prostaglandins 17: 821–830. [CrossRef] [PubMed] [Google Scholar]
  • Garver DL, Holcomb JA, Christensen JD. 2000. Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum. J. Clin. Psychiatry 61: 964–972. [Google Scholar]
  • Glen AI, Glen EM, Horrobin DF, et al. 1994. A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr. Res. 12: 53–61. [CrossRef] [PubMed] [Google Scholar]
  • Glen AI, Cooper SJ, Rybakowski J, Vaddadi K, Brayshaw N, Horrobin DF. 1996. Membrane fatty acids, niacin flushing and clinical parameters. Prostagland. Leukotr. Essent. Fatty Acids 55: 9–15. [CrossRef] [Google Scholar]
  • Hoffer A. 1962. Niacin therapy in psychiatry. Springfield, IL: Charles Thomas. [Google Scholar]
  • Hoppman RA, Peden JG, Over SK. 1991. Central nervous system side effects of nonsteroidal anti-inflammatory drugs. Arch. Intern. Med. 151: 1309–1313. [CrossRef] [PubMed] [Google Scholar]
  • Horrobin DF. 1977. Schizophrenia as a prostaglandin deficiency disease. Lancet 1: 936–937. [CrossRef] [PubMed] [Google Scholar]
  • Horrobin DF. 1980a. Niacin flushing, prostaglandin E and evening primrose oil: a possible objective test for monitoring therapy in schizophrenia. Orthomol. Psychiatry 91: 33–34 [Google Scholar]
  • Horrobin DF. 1980b. Schizophrenia: a biochemical disorder? Biomedicine 32: 54–55. [PubMed] [Google Scholar]
  • Horrobin DF. 1998. The membrane phospholipid hypothesis as a biochemical basis for the neuro-developmental concept of schizophrenia. Schizophr. Res. 30: 193–208. [CrossRef] [PubMed] [Google Scholar]
  • Horrobin DF, Manku MS, Hillman H, Iain A, Glen M. 1991. Fatty acid levels in the brains of schizophrenics and normal controls. Biol. Psychiatry 30: 795–805. [CrossRef] [PubMed] [Google Scholar]
  • Hudson CJ, Kennedy JL, Gotowiec A, et al. 1996. Genetic variant near cytosolic phospholipase A2 associated with schizophrenia. Schizophr. Res. 21: 111–116. [CrossRef] [PubMed] [Google Scholar]
  • Hudson CJ, Lin A, Cogan S, Cashman F, Warsh JJ. 1997. The niacin challenge test: clinical manifestation of altered transmembrane signal transduction in schizophrenia. Biol. Psychiatry 41: 507–513. [CrossRef] [PubMed] [Google Scholar]
  • Jablensky A. 2006 Subtyping schizophrenia: implications for genetic research. Mol. Psychiatry 11: 815–836. [CrossRef] [PubMed] [Google Scholar]
  • Keshavan MS, Tandon R, Boutros NN, Nasrallah HA. 2008. Schizophrenia, just the facts: what we know in 2008 Part 3: neurobiology. Schizophr. Res. 106: 89–107. [CrossRef] [PubMed] [Google Scholar]
  • Khanna N, Altmeyer W Zhuo J, Steven A. 2015 Functional neuroimaging: Fundamental principles and clinical applications. Neuroradiol. J. 28: 87–96. [CrossRef] [PubMed] [Google Scholar]
  • KobzaBlack A, Greaves MW, Hensby CN. 1982. The effect of systemic prednisolone on arachidonic acid, and prostaglandin E2 and F2 alpha levels in human cutaneous inflammation. Br. J. Clin. Pharmacol. 14: 391–394. [CrossRef] [PubMed] [Google Scholar]
  • Kop PG, Zhang D.,Gauthier KM, et al. 2010. Adrenic acid metabolites as endogenous endothelium-derived and zona glomerulosa-derived hyperpolarizing factors. Hypertension 55: 547–554. [Google Scholar]
  • Laan W, Grobbee, D, Selten JP, Heijnen CJ, Kahn RS, Burger H. 2010. Adjuvant asprin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo controlled trial. J. Clin. Psychiatry 71, 520–527. [Google Scholar]
  • Lai E, De Lepeleire I, Crumley TM, et al. 2007. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin. Pharmacol. Ther. 81: 849–857. [CrossRef] [PubMed] [Google Scholar]
  • Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Frackowiak RS. 1992. Patterns of cerebral blood flow in schizophrenia Brit. J. Psychiatry 160: 179–186. [CrossRef] [Google Scholar]
  • Lin SH, Liu CM, Chang SS, et al. 2007. Familial aggregation in skin flush response to niacin patch among schizophrenic patients and their nonpsychotic relatives. Schizophr. Bull. 33: 174–182. [CrossRef] [PubMed] [Google Scholar]
  • Liu CM, Chang SS, Liao SC, et al. 2007. Absent response to niacin skin patch is specific to schizophrenia and independent of smoking. Psychiatr. Res. 152: 181–187. [CrossRef] [Google Scholar]
  • Maciejewski-Lenoir D.,Richman JG, Hakak Y, Gaidarov I, Behan DP, Connolly DT. 2006. Langerhans cells release prostaglandin D2 in response to nicotinic acid. J. Invest. Dermatol. 126: 2637–2646. [CrossRef] [PubMed] [Google Scholar]
  • Maclean R, Ward PE, Glen I, Roberts SJ, Ross BM, 2003. On the relationship between methylnicotinate-induced skin flush and fatty acids levels in acute psychosis. Prog. Neuropsychopharmacol. Biol. Psychiatry. 27: 927–933. [Google Scholar]
  • Mahadik SP, Yao JK. 2006. Phospholipids in schizophrenia. In: Lieberman, J.A., Stroup, T.S., and Perkins, D.O. eds. Textbook of schizophrenia. Washington, DC: The American Psychiatric Publishing, Inc., pp. 117–135. [Google Scholar]
  • Maida ME, Hurley SD, Daeschner JA, Moore AH, O’Banion MK. 2006. Cytosolic prostaglandin E2 synthase (cPGES) expression is decreased in discrete cortical regions in psychiatric disease. Brain Res. 1103: 164–172. [CrossRef] [PubMed] [Google Scholar]
  • Messamore E. 2003. Relationship between the niacin skin flush response and essential fatty acids in schizophrenia. Prostagland. Leukot. Essent. Fatty Acids 69: 413–419. [CrossRef] [Google Scholar]
  • Messamore E. 2012. Niacin subsensitivity is associated with functional impairment in schizophrenia. Schizophr. Res. 137: 180–184 [CrossRef] [PubMed] [Google Scholar]
  • Messamore E, Hoffman WF, Yao JK. 2010. Niacin sensitivity and the arachidonic acid pathway in schizophrenia. Schizophr. Res. 122: 248–256. [CrossRef] [PubMed] [Google Scholar]
  • Miller C.L., Dulay J.R. 2008. The high-affinity niacin receptor HM74A is decreased in the anterior cingulate cortex of individuals with schizophrenia. Brain Res. Bull. 77: 33–41. [CrossRef] [PubMed] [Google Scholar]
  • Mills CM, Hill SA, Marks R. 1997. Transdermal nicotine suppresses cutaneous inflammation. Arch. Dermatol. 133: 823–902 [CrossRef] [PubMed] [Google Scholar]
  • Morrow JD, Parsons WG, Roberts LJ. 1989. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 38: 263–274. [CrossRef] [PubMed] [Google Scholar]
  • Morrow JD, Awad JA, Oates JA, Roberts LJ. 1992. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J. Invest. Dermatol. 98: 812–815. [CrossRef] [PubMed] [Google Scholar]
  • Müller N, Riedel M, Scheppach C, et al. 2002. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am. J. Psychiatry 159: 1029–1034. [CrossRef] [PubMed] [Google Scholar]
  • Murakami M, Kudo I. 2004. Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. Prog. Lipid Res. 43: 3–35. [CrossRef] [PubMed] [Google Scholar]
  • Nilsson BM, Holm G, Hultman CM, Ekselius L. 2015 Cognition and autonomic function in schizophrenia: inferior cognitive test performance in electrodermal and niacin skin flush non-responders Eur. Psychiatry 30: 8–13. [CrossRef] [PubMed] [Google Scholar]
  • Niwa K, Araki E, Morham SG, Ross ME, Iadecola C. 2000. Cyclooxygenase-2 contributes to functional hyperemia in whisker-barrel cortex. J. Neurosci. 20: 763–770. [PubMed] [Google Scholar]
  • Ono N, Abiru T, Kamiya H. 1992. Influences of cyclooxygenase inhibitors on the cataleptic behavior induced by haloperidol in mice. Prostagland. Leukotr. Essent. Fatty Acids 46: 59–63. [CrossRef] [Google Scholar]
  • Papaliodis D, Boucher W, Kempuraj D, et al. 2008. Niacin-induced “flush” involves release of prostaglandin D2 from mast cells and serotonin from platelets: Evidence from human cells in vitro and an animal model. J. Pharmacol. Exp. Ther. 327: 665–672. [CrossRef] [PubMed] [Google Scholar]
  • Peet M. 2007. Membrane fatty acid deficit in schizophrenia and mood disorders. In: Reddy R and Yao JK eds. Fatty acids and oxidative stress in neuropsychiatric disorders. New York: Nova Science Publishers, Inc., pp. 101–114. [Google Scholar]
  • Peet M, Laugharne JDE, Horrobin DF, Reynolds GP. 1994. Arachidonic acid: A common link in the biology of schizophrenia? Arch. Gen. Psychiatry 51: 665–666. [CrossRef] [PubMed] [Google Scholar]
  • Peet M, Horrobin DF, Group EEMS. 2002. A dose ranging exploratory study of the effects of ethyleicosapentaenoate in patients with persistent schizophrenic symptoms. J. Psychiatr. Res. 36: 7–18. [CrossRef] [PubMed] [Google Scholar]
  • Pettegrew JW, Keshavan MS, Panchalingam K, et al. 1991. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch. Gen. Psychiatry. 48: 563–568. [CrossRef] [PubMed] [Google Scholar]
  • Plummer NA, Hensby CN, Black AK, Greaves MW. 1977. Prostaglandin activity in sustained inflammation of human skin before and after aspirin. Clin. Sci. Mol. Med. 52: 615–620. [PubMed] [Google Scholar]
  • Puri BK, Easton T, Das I, Kidane L, Richardson AJ. 2001. The niacin skin flush test in schizophrenia: a replication study. Int. J. Clin. Pract. 55: 368–370. [PubMed] [Google Scholar]
  • Puri BK, Hirsch SR, Easton T, Richardson AJ. 2002. A volumetric biochemical niacin flush based index that noninvasively detects fatty acid deficiency in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 26: 49–52. [CrossRef] [PubMed] [Google Scholar]
  • Puri BK, Richardson AJ, Counsell SJ, et al. 2007. Negative correlation between cerebral inorganic phosphate and the volumetric niacin response in male patients with schizophrenia who have seriously and dangerously violently offended: a (31)P magnetic resonance spectroscopy study. Prostagland. Leukot. Essent. Fatty Acids 77: 97–99. [CrossRef] [Google Scholar]
  • Reddy RD, Keshavan MS, Yao JK. 2004. Reduced red blood cell membrane polyunsaturated fatty acids in first-episode schizophrenia at neuroleptic-naïve baseline. Schizophr. Bull. 30: 901–911. [CrossRef] [PubMed] [Google Scholar]
  • Ross BM, Hughes B, Turenne S, Seeman M, Warsh JJ. 2004. Reduced vasodilatory response to methyl-nicotinate in schizophrenia as assessed by laser doppler flowmetry. Eur. Neuropsychopharma 14: 191–197. [CrossRef] [Google Scholar]
  • Shah SH, Ramchand CN, Peet M. 1999. The niacin skin flush test: first-degree relatives show responses intermediate between patients and controls. Schizophr. Res. 36: 314. [Google Scholar]
  • Shah SH, Vankar GK, Peet M, Ramchand CN. 2000. Unmedicated schizophrenic patients have a reduced skin flush in response to topical niacin. Schizophr. Res. 43: 163–164. [PubMed] [Google Scholar]
  • Skosnik PD, Yao JK. 2003. From phospholipid and fatty acid defects to altered neurotransmission: Is arachidonic acid a nexus in the pathophysiology of schizophrenia? Prostagland. Leukot. Essent. Fatty Acids 69: 367–384 [CrossRef] [Google Scholar]
  • Smesny S, Riemann S, Riehemann S, Bellemann ME, Sauer H. 2001. Quantitative measurement of induced skin reddening using optical reflection spectroscopy–methodology and clinical application. Biomed. Tech. (Berl). 46: 280–286. [CrossRef] [PubMed] [Google Scholar]
  • Smesny S, Berger G, Rosburg T, et al. 2003. Potential use of the topical niacin skin test in early psychosis a combined approach using optical reflection spectroscopy and a descriptive rating scale. J. Psychiatr. Res. 37: 237–247. [CrossRef] [PubMed] [Google Scholar]
  • Snyder SH. 1981. Dopamine receptors, neuroleptics, and schizophrenia. Am. J. Psychiatry. 138: 460–464. [CrossRef] [PubMed] [Google Scholar]
  • Sussman N, Magid S. 2000. Psychiatric manifestations of nonsteroidal antiinflammatory drugs. Primary Psychiatry 7: 26–30. [Google Scholar]
  • Svedmyr N, Heggelund A, Aberg G, 1977. Influence of indomethacin on flush induced by nicotinic acid in man. Acta. Pharmacol. Toxicol. 41: 397–400. [CrossRef] [Google Scholar]
  • Tang Y, Zhou L, Gunnet JW, Wines PG, Cryan EV, Demarest KT. 2006. Enhancement of arachidonic acid signaling pathway by nicotinic acid receptor HM74A. Biochem. Biophys. Res. Commun. 345: 29–37. [CrossRef] [PubMed] [Google Scholar]
  • Tavares H, Yacubian J, Talib LL, Barbosa NR, Gattaz WF. 2003. Increased phospholipase A2 activity in schizophrenia with absent response to niacin. Schizophr. Res. 61: 1–6. [CrossRef] [PubMed] [Google Scholar]
  • Turenne SD, Seeman M, Ross BM. 2001. An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine, and nicotine upon nicotinic acid response Schizophr. Res. 50: 191–197 [CrossRef] [PubMed] [Google Scholar]
  • Urade Y, Ujihara M, Horiguchi Y, Ikai K, Hayaishi O. 1989. The major source of endogenous prostaglandin D2 production is likely antigen-presenting cells. Localization of glutathione-requiring prostaglandin D synthetase in histiocytes, dendritic, and Kupffer cells in various rat tissues. J. Immunol. 143: 2982–2989. [PubMed] [Google Scholar]
  • Vaddadi KS, Gilleard CJ, Mindham RHButler R. 1986. A controlled trial of prostaglandin E1 precursor in chronic neuroleptic resistant schizophrenic patients. Psychopharmacol. 88: 362–367. [CrossRef] [Google Scholar]
  • Waldo MC. 1999. Co-distribution of sensory gating and impaired niacin flush response in the parents of schizophrenics. Schizophr. Res. 40: 49–53. [CrossRef] [PubMed] [Google Scholar]
  • Wanibuchi F, Usuda S. 1990. Synergistic effects between D-I and D-2 dopamine antagonists on catalepsy in rats. Psychopharmacology 102: 339–342. [CrossRef] [PubMed] [Google Scholar]
  • Ward PE, Sutherland J, Glen EM, Glen AI. 1998. Niacin skin flush in schizophrenia: a preliminary report. Schizophr. Res. 29: 269–274. [CrossRef] [PubMed] [Google Scholar]
  • Weinberger DR, Berman KF, Suddath R, Torrey EF. 1992. Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am J. Psychiatry. 149: 890–897. [CrossRef] [PubMed] [Google Scholar]
  • Wilkin JK, Wilkin O, Kapp R, Donachie R, Chernosky ME, Buckner J. 1982. Aspirin blocks nicotinic acid-induced flushing. Clin. Pharmacol. Ther. 31: 478–482. [CrossRef] [PubMed] [Google Scholar]
  • Winklemann RK, Wilhelmj CM, Horner FA. 1965. Experimental studies on dermographism. Arch. Dermatol. 92: 436–442. [CrossRef] [PubMed] [Google Scholar]
  • Yao JK. 2003. Abnormalities of fatty acid metabolism in red cells, platelets and brain in schizophrenia. In: Peet M, Glen I, Horrobin DF, eds., Phospholipid spectrum disorders in psychiatry and neurology, 2nd ed. Lancashire, UK: Marius Press, pp. 193–212. [Google Scholar]
  • Yao JK, van Kammen DP, Welker JA. 1994a. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr. Res. 13: 217–226. [CrossRef] [PubMed] [Google Scholar]
  • Yao JK, van Kammen DP, Gurklis J. 1994b. Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures. Schizophr. Res. 13: 227–232. [CrossRef] [PubMed] [Google Scholar]
  • Yao JK, Leonard S, Reddy R. 2000. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr. Res. 42: 7–17. [CrossRef] [PubMed] [Google Scholar]
  • Yao JK, Dougherty GG, Reddy RD, et al. 2010a. Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia. PLoS One 5: e9508. [CrossRef] [PubMed] [Google Scholar]
  • Yao JK, Dougherty GG, Reddy RD, et al. 2010b. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naïve patients with schizophrenia. Mol. Psychiatry. 15: 938–953. [CrossRef] [PubMed] [Google Scholar]
  • Yao JK, Dougherty Jr GG, Gautier CH, et al. 2015. Prevalence and specificity of the abnormal niacin response: A potential endophenotype marker in schizophrenia. Schizophr. Bull. DOI: 10.1093/schbul/sbv130. [Google Scholar]
  • Zonta M, Angulo MC, Gobbo S, Rosengarten B, Hossmann KA, Pozzan T, Carmignot G. 2003. Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation. Nat. Neurosci. 6: 43–50. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.